Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Huang, Huey Lan ^a   Chen, Yu Chieh ^a   Huang, Yu Chuen ^b,c   Yang, Kai Chien ^d   Pan, Hsin yi ^a   Shih, Shou Ping ^a   Chen, Yu Jen ^d,e,f  

^a CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY PROTEIN 5; BECLIN 1; LAPATINIB; MEMBRANE PROTEIN; PROTEIN ATG7; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL DIFFERENTIATION; CELL STRAIN K 562; CELL STRUCTURE; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEGAKARYOCYTE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; UPREGULATION; CYTOLOGY; FLOW CYTOMETRY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL DIFFERENTIATION; FLOW CYTOMETRY; HUMANS; K562 CELLS; MEGAKARYOCYTES; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84055207507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029014     Document Type: Article

References (53)

1. Holbro T, Hynes NE, (2004) ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44: 195-217.
2. Kopper L, (2008) Lapatinib: a sword with two edges. Pathol Oncol Res 14: 1-8.
3. Ito Y, Tokudome N, Sugihara T, Takahashi S, Hatake K, (2007) Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? Breast Cancer 14: 156-162.
4. Swanton C, Futreal A, Eisen T, (2006) Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 12: 4377s-4383s.
5. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ, (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118-11128.
6. Nahta R, Yuan LX, Du Y, Esteva FJ, (2007) Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6: 667-674.
7. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, et al. (2009) A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 15: 5895-5901.
8. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, et al. (2009) A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64: 777-783.
9. Steeghs N, Nortier JW, Gelderblom H, (2007) Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 14: 942-953.
10. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, et al. (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85-94.
11. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, et al. (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24: 6213-6221.
12. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639.
13. Zhou Y, Li S, Hu YP, Wang J, Hauser J, et al. (2006) Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 66: 404-411.
14. Spira AI, Carducci MA, (2003) Differentiation therapy. Curr Opin Pharmacol 3: 338-343.
15. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C, (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279.
16. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, et al. (2009) Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16: 3-11.
17. Honma Y, Matsuo Y, Hayashi Y, Omura S, (1995) Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor. Int J Cancer 60: 685-688.
18. Morceau F, Dupont C, Palissot V, Borde-Chiche P, Trentesaux C, et al. (2000) GTP-mediated differentiation of the human K562 cell line: transient overexpression of GATA-1 and stabilization of the gamma-globin mRNA. Leukemia 14: 1589-1597.
19. Huang YC, Chao DK, Clifford Chao KS, Chen YJ, (2009) Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells. Toxicol In Vitro 23: 979-985.
20. Colosetti P, Puissant A, Robert G, Luciano F, Jacquel A, et al. (2009) Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line. Autophagy 5: 1092-1098.
21. Imai K, Takaoka A, (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727.
22. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, et al. (2009) Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci 100: 1701-1707.
23. Tetteroo PA, Massaro F, Mulder A, Schreuder-van Gelder R, von dem Borne AE, (1984) Megakaryoblastic differentiation of proerythroblastic K562 cell-line cells. Leuk Res 8: 197-206.
24. Olaussen KA, Commo F, Tailler M, Lacroix L, Vitale I, et al. (2009) Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene 28: 4249-4260.
25. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, et al. (2007) Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40: 580-594.
26. Djavaheri-Mergny M, Amelotti M, Mathieu J, Besancon F, Bauvy C, et al. (2007) Regulation of autophagy by NFkappaB transcription factor and reactives oxygen species. Autophagy 3: 390-392.
27. Bell BD, Walsh CM, (2009) Coordinate regulation of autophagy and apoptosis in T cells by death effectors: FADD or foundation. Autophagy 5: 238-240.
28. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175.
29. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, et al. (2009) Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 16: 1093-1107.
30. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, et al. (2009) Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 8: 2084-2096.
31. Wang J, Whiteman MW, Lian H, Wang G, Singh A, et al. (2009) A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1. J Biol Chem 284: 21412-21424.
32. Fader CM, Colombo MI, (2006) Multivesicular bodies and autophagy in erythrocyte maturation. Autophagy 2: 122-125.
33. Fader CM, Sanchez D, Furlan M, Colombo MI, (2008) Induction of autophagy promotes fusion of multivesicular bodies with autophagic vacuoles in k562 cells. Traffic 9: 230-250.
34. Chen YJ, Huang WP, Yang YC, Lin CP, Chen SH, et al. (2009) Platonin induces autophagy-associated cell death in human leukemia cells. Autophagy 5: 173-183.
35. Yu L, Alva A, Su H, Dutt P, Freundt E, et al. (2004) Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 304: 1500-1502.
36. Declercq W, Vanden Berghe T, Vandenabeele P, (2009) RIP kinases at the crossroads of cell death and survival. Cell 138: 229-232.
37. Boehrer S, Ades L, Braun T, Galluzzi L, Grosjean J, et al. (2008) Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 111: 2170-2180.
38. Boehrer S, Ades L, Galluzzi L, Tajeddine N, Tailler M, et al. (2008) Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochem Pharmacol 76: 1417-1425.
39. Pitini V, Arrigo C, Altavilla G, (2008) Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol 26: 3645-3646.
40. Lindhagen E, Eriksson A, Wickstrom M, Danielsson K, Grundmark B, et al. (2008) Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 81: 344-353.
41. Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, et al. (2008) Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia 22: 1624-1627.
42. Ravindranathan M, Klementich FJ, Jones DV Jr, (2007) Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia. Leukemia 21: 2546-2547.
43. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, et al. (2005) Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106: 2841-2848.
44. Takigawa N, Takeuchi M, Shibayama T, Yoshida I, Kawata N, et al. (2005) Successful treatment of a patient with synchronous advanced non-small cell lung cancer and acute myeloid leukemia by a combination of gefitinib, low-dose cytarabine and aclarubicin. Anticancer Res 25: 2579-2582.
45. Ennishi D, Sezaki N, Senoo T, Terui Y, Hatake K, et al. (2006) A case of acute promyelocytic leukemia during gefitinib treatment. Int J Hematol 84: 284-285.
46. Chan G, Pilichowska M, (2007) Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 110: 1079-1080.
47. Bhutia SK, Dash R, Das SK, Azab B, Su ZZ, et al. (2010) Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res 70: 3667-3676.
48. Buhring HJ, Sures I, Jallal B, Weiss FU, Busch FW, et al. (1995) The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood 86: 1916-1923.
49. Allen H, Hsuan J, Clark S, Maziarz R, Waterfield MD, et al. (1990) Expression of epidermal-growth-factor receptor in the K562 cell line by transfection. Altered receptor biochemistry. Biochem J 271: 785-790.
50. Muller MR, Grunebach F, Kayser K, Vogel W, Nencioni A, et al. (2003) Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res 9: 3448-3453.
51. Spengeman JD, Green TD, McCubrey JA, Bertrand FE, (2005) Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells. Cell Cycle 4: 483-487.
52. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, et al. (2007) The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 21: 886-896.
53. Lakshmikuttyamma A, Pastural E, Takahashi N, Sawada K, Sheridan DP, et al. (2008) Bcr-Abl induces autocrine IGF-1 signaling. Oncogene 27: 3831-3844.